2013-2022年中国早期临床试验的变化:一篇综述
Jianxiong Zhang1, Peng Zhang2, Haixue Wang3
1Research Ward, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
Drugs in R&D
|September 12, 2024
概括
中国中国中国中国.
科学领域:
- 制药科学 制药科学
- 临床研究 临床研究
- 药物开发 药物开发
背景情况:
- 中国的制药行业正在经历创新药物临床试验的快速增长.
- 政府的政策显著提高了研究和开发的热情.
- 分析了2013-2022年中国药物评估中心 (CDE) 的早期临床试验数据.
研究的目的:
- 分析中国早期临床试验的趋势和特征.
- 评估政府政策对药物开发的影响.
- 确定未来改善临床试验效率的关键领域.
主要方法:
- 总结了在CDE注册的5336项早期临床试验的数据.
- 分析包括试验注册时间,药物分类,说明和试验状态.
- 检查了试验数量,生长率,药物类型和治疗领域的趋势.
主要成果:
- 早期临床试验的数量和增长速度同比大幅增加.
- 化学药物在试验中占主导地位,但从2013年的85.7%降至2022年的59.5%.
- 瘤学药物每年显著增加,到2022年达到49.2%的试验.
结论:
- 在政府支持和先进技术的推动下,中国的早期临床试验开发在2013-2022年期间取得了重大进展.
- 持续的进步需要先进的技术支持和增强的标准化监督系统.
- 瘤药物试验的增加凸显了未来制药创新的关键重点领域.
相关概念视频
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
124
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
124
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Hazard Ratio
96
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
For example, in a clinical trial...
96


